🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesSemaglutide cardiovascular benefit independent of weight loss Page 2

Semaglutide cardiovascular benefit independent of weight loss

Dr.CardioMD Mon, Jun 8, 2026 at 6:52 AM 11 replies 302 viewsPage 2 of 3
stefan_berlin
Member
234
1,123
Oct 2024
Berlin, DE
Jun 8, 2026 at 9:23 AM#6

One concrete data point for the thread. For anyone assembling their own picture: Tmax is one to three days, terminal half-life about 165 to 170 hours, steady state at four to five weeks, and subcutaneous bioavailability near 89%. Those four numbers explain most of the questions people ask about timing.

3 23NeuroNate, JessicaH_TX, KevinCompounds
Reply Quote Save Share Report
tammy_FL
Member
234
890
Nov 2024
Tampa, FL
Jun 8, 2026 at 10:22 AM#7

Following on from julia.endo — and this may be the naive question:

How much of the between-person variation is pharmacokinetic and how much is just adherence measured badly?

2 22alex_tucson, kevin_tulsa
Reply Quote Save Share Report
NurseKim_ATL
Senior Member
1,678
7,234
Feb 2024
Atlanta, GA
Jun 8, 2026 at 11:21 AM#8
stefan_berlin said:
For anyone assembling their own picture: Tmax is one to three days, terminal half-life about 165 to 170 hours, steady state at four to five weeks, and…

Adding the part of the answer the thread has not reached. The dose-response is real but shallow at the top. Across STEP 1 and STEP 4 the gap between 1.7mg and 2.4mg is a couple of percentage points of body weight on average, and the average is carrying a wide spread — plenty of people at 1.7mg sit above the 2.4mg mean. If a dose is working and tolerable, "working" is the relevant variable, not "maximal".

1 21ingrid_STO
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
Dr.CardioMD
VIP Member
2,678
14,567
Dec 2023
Cleveland, OH
Jun 8, 2026 at 12:20 PM#9

OP back with an update, since a thread like this is useless without one.

Following this thread I went back and re-read the extension data properly. The point about trough rather than peak explains the pattern I was seeing on day six, which I had been blaming on the vial.

50 20roxy_nash, tony_orlando, Dr.NephBHM_UK and 47 others
Reply Quote Save Share Report
Dr.KarenChen
VIP Member
4,210
24,567
Nov 2023
San Francisco, CA
Jun 8, 2026 at 5:04 PM#10
NurseKim_ATL said:
The dose-response is real but shallow at the top.

Agreed, though "tolerable" needs defining. A dose you tolerate by eating almost nothing is not tolerated, it is being paid for somewhere else — usually in lean mass, sometimes in adherence three months later.

Last edited: Jun 8, 2026 at 11:04 PM
20 20sarah_nash92, FitDadDave, RunnerRach and 17 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
Blood pressure reduction mechanisms on GLP-1 — natriuresis18 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register